Works matching IS 15228517 AND DT 2022 AND VI 24 AND IP 5
Results: 23
Forthcoming Meetings.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 852, doi. 10.1093/neuonc/noac091
- Publication type:
- Article
Enhancing demethylation-induced differentiation in IDH-mutant glioma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 724, doi. 10.1093/neuonc/noac056
- By:
- Publication type:
- Article
Neural networks help zebrafish to step up as a model for efficient drug screening in glioblastoma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 739, doi. 10.1093/neuonc/noac045
- By:
- Publication type:
- Article
Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 851, doi. 10.1093/neuonc/noac028
- By:
- Publication type:
- Article
Repurposing the drug verteporfin as anti-neoplastic therapy for glioblastoma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 708, doi. 10.1093/neuonc/noac019
- By:
- Publication type:
- Article
Volumetric measurements in low-grade glioma: Are we there yet?
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 779, doi. 10.1093/neuonc/noac018
- By:
- Publication type:
- Article
Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 694, doi. 10.1093/neuonc/noab244
- By:
- Publication type:
- Article
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 755, doi. 10.1093/neuonc/noab243
- By:
- Publication type:
- Article
IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 809, doi. 10.1093/neuonc/noab239
- By:
- Publication type:
- Article
molecularly integrated grade for meningioma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 796, doi. 10.1093/neuonc/noab213
- By:
- Publication type:
- Article
Trabectedin for recurrent WHO grade 2 or 3 meningiomas—Paving the road for new opportunities.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 768, doi. 10.1093/neuonc/noac017
- By:
- Publication type:
- Article
Clinical management of desmoplastic myxoid tumor, SMARCB1-mutant.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 847, doi. 10.1093/neuonc/noac016
- By:
- Publication type:
- Article
Balancing maximal resection and functional preservation in surgery for low-grade glioma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 794, doi. 10.1093/neuonc/noac008
- By:
- Publication type:
- Article
Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: A longitudinal, within-patient design study.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 781, doi. 10.1093/neuonc/noab275
- By:
- Publication type:
- Article
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 669, doi. 10.1093/neuonc/noab269
- By:
- Publication type:
- Article
Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 741, doi. 10.1093/neuonc/noab268
- By:
- Publication type:
- Article
Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 726, doi. 10.1093/neuonc/noab264
- By:
- Publication type:
- Article
Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 711, doi. 10.1093/neuonc/noab263
- By:
- Publication type:
- Article
Proton vs photon radiation therapy for glioblastoma: Maximizing information from trial.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 849, doi. 10.1093/neuonc/noab261
- By:
- Publication type:
- Article
Consensus core clinical data elements for meningiomas (v2021.1).
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 683, doi. 10.1093/neuonc/noab259
- By:
- Publication type:
- Article
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 770, doi. 10.1093/neuonc/noab256
- By:
- Publication type:
- Article
12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 834, doi. 10.1093/neuonc/noab246
- By:
- Publication type:
- Article
Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 821, doi. 10.1093/neuonc/noab245
- By:
- Publication type:
- Article